(2017) Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside. Caspian Journal of Internal Medicine. pp. 228-238. ISSN 2008-6164
Text
Promising role for Gc-MAF in cancer immunotherapy from bench to bedside.pdf Download (560kB) |
Abstract
Immunotherapy has been used for years in many types of cancer therapy. Recently, cancer immunotherapy has focused on mechanisms which can enhance the development of cell-mediated immunity. Anticancer medications are administered to inhibit immunosuppressive factors such as nagalase enzyme, which is produced by neoplastic cells and destroys macrophage activating factor (Gc-MAF). Anti-neoplastics medications can also enhance immune-cell activity against tumors. Such medications show great potential in cancer immunotherapy using natural human mechanisms against neoplasms.
Item Type: | Article |
---|---|
Keywords: | Cancer Immunotherapy Macrophage activating factor Gc-MAF Vitamin D macrophage-activating factor d-binding protein alpha-n-acetylgalactosaminidase cell lung-cancer mouse peritoneal-macrophages vitamin d-3-binding protein metastatic breast-cancer ehrlich ascites tumor vitamin-d-3-binding protein sonodynamic therapy General & Internal Medicine |
Divisions: | |
Page Range: | pp. 228-238 |
Journal or Publication Title: | Caspian Journal of Internal Medicine |
Journal Index: | ISI |
Volume: | 8 |
Number: | 4 |
Identification Number: | https://doi.org/10.22088/cjim.8.4.228 |
ISSN: | 2008-6164 |
Depositing User: | مهندس مهدی شریفی |
URI: | http://eprints.bmsu.ac.ir/id/eprint/4645 |
Actions (login required)
View Item |